Saturday 17 October 2026
Export EPRX’s income statement to Excel — free account
Eupraxia Pharmaceuticals Inc.
EPRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 11.5% and free cash flow fell 56.4%, each against the same quarter a year earlier.
6.62
0.15
−2.22%
Follow EPRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (117.82%) | (92.32%) | (161.71%) | (98.00%) |
+8 more TTM periods Free account |
|
| (64.44%) | (53.82%) | (67.89%) | (61.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(40.69%) | (34.56%) | (51.19%) | (35.92%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.58) | (0.59) | (0.73) | (0.68) | |
Free Cash Flow |
(38.23) | (33.44) | (29.14) | (25.24) | |
Capital Expenditures |
(0.75) | (0.75) | (0.59) | (0.44) | |
| Other line items | |||||
Cash ROIC |
(14.42%) | (12.08%) | (18.09%) | (14.22%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.70 | 0.69 | 0.78 | |
Depreciation/Fixed assets |
0.30 | 0.24 | 0.28 | 0.32 | |
Capex/Depreciation |
(2.09) | (2.66) | (2.48) | (2.00) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.57) | (0.58) | (0.71) | (0.67) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates